Outstanding Recoveries

• Home
• Outstanding Recoveries

Verdicts & Settlements

• 

  $62 Million Settlement – Comverse Technology, Inc. Derivative Litigation

  In re Comverse Technology, Inc. Derivative Litigation, No. 601272/2006 (N.Y. Sup. Ct. N.Y. Cnty.)

  See More

  As Co-Lead Counsel, Milberg negotiated a $62 settlement which was approved by the court in 2010. The settlement also resulted in significant corporate governance reforms, including the replacement of various directors and officers; the amendment of the company’s bylaws to permit certain shareholders to propose in the company’s proxy materials nominees for election as directors; and the requirement that all equity grants be approved by both the compensation committee and a majority of the non-employee directors.
• 

  $7.5 Million Settlement – Meritage Homes of the Carolinas, Inc. v. Town of Holly Springs

  Meritage Homes of the Carolinas, Inc. v. Town of Holly Springs, Wake Co. File No. 20-CVS-14511 (NC)

  See More

  $7.5 million class settlement on behalf of developers for illegal recreation fees in lieu of land dedication.
• 

  $1+ Billion Settlement – NASDAQ Market-Makers Antitrust Litigation

  In re NASDAQ Market-Makers Antitrust Litigation, No. 94-3996 (S.D.N.Y.)

  See More

  Milberg served as Co-Lead Counsel for a class of investors alleging that NASDAQ market-makers set wide spreads pursuant to an industry-wide conspiracy in one of the largest and most important antitrust cases in recent history. Following more than three years of litigation, the case settled for over $1 billion.
• 

  $68.5 Million Settlement – Parris, et al. v. Meta Platforms

  Parris, et al., v. Meta Platforms, Inc., Case No.2023LA000672 (18th Cir. DuPage Cty., Ill.)

  See More

  Milberg served as Lead Counsel in this privacy class action under the Illinois Biometric Information Privacy Act. Milberg obtained a settlement of $68.5 million in 2023.
• 

  $138 Million Settlement – Biovail Corp. Securities Litigation

  In re Biovail Corp. Securities Litigation, No. 03-8917 (S.D.N.Y.)

  See More

  Milberg, representing Local 282 Welfare Trust Fund and serving as Co-Lead Counsel, litigated this securities action alleging that defendants made misleading statements concerning Biovail’s financial results and its drug, Cardizem LA. Following substantial discovery, including depositions across the U.S. and Canada, Milberg obtained a $138 million settlement for the class, and Biovail agreed to institute significant corporate governance changes.